Bayer's Kogenate FS (recombinant antihemophilic Factor VIII) has been approved for the prophylaxis of hemophilia A in children 0-16 years of age without pre-existing joint damage. This approval was based on a clinical trial of 65 boys under 30 months old with severe hemophilia A that showed 93% of patients in the prophylaxis group had normal joint function versus 55% in an episodic group. In addition, the prophylaxis group had an 81.5% reduction in annual bleeding frequency and an 83% reduction in the risk of joint damage compared to the episodic group.

Kogenate FS is already approved for the prevention and control of hemorrhagic episodes in Hemophilia A patients.

For more information call (800) 288-8371 or visit www.kogenatefs.com.